Technical Analysis for TGTX - TG Therapeutics, Inc.

Grade Last Price % Change Price Change
grade D 49.62 -3.07% -1.57
TGTX closed down 3.07 percent on Friday, January 15, 2021, on 83 percent of normal volume.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Down
Historical TGTX trend table...

Date Alert Name Type % Chg
1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
Multiple of Ten Bearish Other 0.00%
BB Squeeze + Lower Band Touch Range Contraction 0.00%
Below Lower BB Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Fell Below 20 DMA Bearish -3.07%
1,2,3 Pullback Bullish Bullish Swing Setup -3.07%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -3.07%
Older End-of-Day Signals for TGTX ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Lower Bollinger Band Support about 23 hours ago
Down 5% 1 day ago
Down 3% 1 day ago
Down 2 % 1 day ago
Fell Below Lower Bollinger Band 1 day ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

TG Therapeutics, Inc. Description

TG Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of innovative and medically important pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. The company is developing two advanced therapies targeting hematological malignancies. The TGTX-1101 (ublituximab) is a novel, third generation monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes, which is in clinical development for patients with relapsed and refractory non-Hodgkin's lymphoma. The TGR-1202 is an orally available PI3K delta inhibitor believed to be important in the proliferation and survival of B-lymphocytes. TG Therapeutics, Inc. is headquartered in New York, New York.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Clinical Development Treatment Of Cancer Pharmaceutical Products Monoclonal Antibodies Monoclonal Antibody Lymphoma Antibody Drug Conjugates Hematological Malignancies Camidanlumab Tesirine Cd20 Lymphocytes

Is TGTX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 56.74
52 Week Low 6.34
Average Volume 2,156,060
200-Day Moving Average 25.81
50-Day Moving Average 40.16
20-Day Moving Average 52.59
10-Day Moving Average 52.07
Average True Range 2.84
ADX 42.22
+DI 30.65
-DI 19.17
Chandelier Exit (Long, 3 ATRs ) 48.23
Chandelier Exit (Short, 3 ATRs ) 53.66
Upper Bollinger Band 55.29
Lower Bollinger Band 49.90
Percent B (%b) -0.05
BandWidth 10.25
MACD Line 3.08
MACD Signal Line 4.17
MACD Histogram -1.0885
Fundamentals Value
Market Cap 6.28 Billion
Num Shares 127 Million
EPS -1.96
Price-to-Earnings (P/E) Ratio -25.33
Price-to-Sales 20013.68
Price-to-Book 21.66
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 54.08
Resistance 3 (R3) 54.23 52.88 53.34
Resistance 2 (R2) 52.88 51.74 52.81 53.09
Resistance 1 (R1) 51.25 51.04 50.58 51.11 52.84
Pivot Point 49.91 49.91 49.57 49.83 49.91
Support 1 (S1) 48.27 48.77 47.60 48.13 46.40
Support 2 (S2) 46.93 48.07 46.86 46.15
Support 3 (S3) 45.30 46.93 45.90
Support 4 (S4) 45.16